Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2019 3
2020 1
2021 1
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for z nikpour
Your search for Z Nikpouri retrieved no results
GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways.
López-Isac E, Acosta-Herrera M, Kerick M, Assassi S, Satpathy AT, Granja J, Mumbach MR, Beretta L, Simeón CP, Carreira P, Ortego-Centeno N, Castellvi I, Bossini-Castillo L, Carmona FD, Orozco G, Hunzelmann N, Distler JHW, Franke A, Lunardi C, Moroncini G, Gabrielli A, de Vries-Bouwstra J, Wijmenga C, Koeleman BPC, Nordin A, Padyukov L, Hoffmann-Vold AM, Lie B; European Scleroderma Group†; Proudman S, Stevens W, Nikpour M; Australian Scleroderma Interest Group (ASIG); Vyse T, Herrick AL, Worthington J, Denton CP, Allanore Y, Brown MA, Radstake TRDJ, Fonseca C, Chang HY, Mayes MD, Martin J. López-Isac E, et al. Nat Commun. 2019 Oct 31;10(1):4955. doi: 10.1038/s41467-019-12760-y. Nat Commun. 2019. PMID: 31672989 Free PMC article.
Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis.
Kerick M, Acosta-Herrera M, Simeón-Aznar CP, Callejas JL, Assassi S; International SSc Group; Proudman SM, Nikpour M; Australian Scleroderma Interest Group (ASIG); PRECISESADS Clinical Consortium; Hunzelmann N, Moroncini G, de Vries-Bouwstra JK, Orozco G, Barton A, Herrick AL, Terao C, Allanore Y, Fonseca C, Alarcón-Riquelme ME, Radstake TRDJ, Beretta L, Denton CP, Mayes MD, Martin J. Kerick M, et al. NPJ Genom Med. 2022 Oct 5;7(1):57. doi: 10.1038/s41525-022-00327-8. NPJ Genom Med. 2022. PMID: 36198672 Free PMC article.
The RNA binding activity of the first identified trypanosome protein with Z-DNA-binding domains.
Nikpour N, Salavati R. Nikpour N, et al. Sci Rep. 2019 Apr 11;9(1):5904. doi: 10.1038/s41598-019-42409-1. Sci Rep. 2019. PMID: 30976048 Free PMC article.
Using sensitive database searches and experimental data, we identify Z-DNA-binding domains in T. brucei in the N- and C-terminal regions of Tb927.10.7910. RNA-binding studies of the wild-type protein, now referred to as RBP7910 (RNA binding protein 7910), and site-directed …
Using sensitive database searches and experimental data, we identify Z-DNA-binding domains in T. brucei in the N- and C-terminal regi …
The national health program for vitamin D supplementation in a developing country.
Saberi-Karimian M, Ghazizadeh H, Zanganeh Baygi M, Minaie M, Sadeghi F, Pouraram H, Elmadfa I, Esmaily H, Khadem Rezaian M, Tavallaei S, Mohammadi Bajgiran M, Zare Feyz-Abadi R, Timar A, Sharifan P, Bahrami Taghanaki H, Gholian M, Farahmand SK, Abasalti Z, Farkhani EM, Akhgari A, Smailzadeh A, Izanloo H, Nikpour M, Haghveysi A, Mohammadkarimi A, Yaghoubi A, Rahimi A, Tabatabaei SM, Sheikhzadeh K, Sheikhi M, Shahraki F, Farajian F, Salehizadeh M, Khanavi M, Ghanouni F, Goudarzi S, Ferns GA, Abdollahi Z, Ghayour-Mobarhan M. Saberi-Karimian M, et al. Clin Nutr ESPEN. 2023 Apr;54:52-59. doi: 10.1016/j.clnesp.2023.01.012. Epub 2023 Jan 20. Clin Nutr ESPEN. 2023. PMID: 36963898
Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes.
Acosta-Herrera M, Kerick M, Lopéz-Isac E, Assassi S, Beretta L, Simeón-Aznar CP, Ortego-Centeno N; International SSc Group; Proudman SM; Australian Scleroderma Interest Group (ASIG); Hunzelmann N, Moroncini G, de Vries-Bouwstra JK, Orozco G, Barton A, Herrick AL, Terao C, Allanore Y, Brown MA, Radstake TR, Fonseca C, Denton CP, Mayes MD, Martin J. Acosta-Herrera M, et al. Ann Rheum Dis. 2021 Aug;80(8):1040-1047. doi: 10.1136/annrheumdis-2021-219884. Epub 2021 Apr 1. Ann Rheum Dis. 2021. PMID: 34096881 Free PMC article.
In vitro evaluation of anti-herpes simplex-1 activity of three standardized medicinal plants from Lamiaceae.
Ansari M, Sharififar F, Arabzadeh AM, Mehni F, Mirtadzadini M, Iranmanesh Z, Nikpour N. Ansari M, et al. Anc Sci Life. 2014 Jul-Sep;34(1):33-8. doi: 10.4103/0257-7941.150777. Anc Sci Life. 2014. PMID: 25737608 Free PMC article.
RESULTS: Among the tested extracts, T. polium contained the highest percentage of RA (1.8%w/w) and exhibited the least toxicity (MNTC = 1000 mug/ml). The greatest anti-HSV-1 was shown by T. polium and Z. clinopoides extracts which exhibited both time and concentration-depe …
RESULTS: Among the tested extracts, T. polium contained the highest percentage of RA (1.8%w/w) and exhibited the least toxicity (MNTC = 1000 …
Clinical Trial: CYP2D6 Related Dose Escalation of Tamoxifen in Breast Cancer Patients With Iranian Ethnic Background Resulted in Increased Concentrations of Tamoxifen and Its Metabolites.
Khalaj Z, Baratieh Z, Nikpour P, Schwab M, Schaeffeler E, Mokarian F, Khanahmad H, Salehi R, Mürdter TE, Salehi M. Khalaj Z, et al. Front Pharmacol. 2019 May 24;10:530. doi: 10.3389/fphar.2019.00530. eCollection 2019. Front Pharmacol. 2019. PMID: 31178724 Free PMC article.
The concentration of tamoxifen and its metabolites before and after 4 and 8 months of dose adjustment were measured using LC-MS/MS technology. Results: At baseline, (Z)-endoxifen plasma concentrations (33 15.5, 28.1 14, 26.6 23.4, 14.3 8.6, and 10.7 5.5 nmol/l for EM/EM, E …
The concentration of tamoxifen and its metabolites before and after 4 and 8 months of dose adjustment were measured using LC-MS/MS technolog …
Comparison of Attainment and Protective Effects of Lupus Low Disease Activity State In Patients With Newly Diagnosed Versus Established Systemic Lupus Erythematosus.
Golder V, Kandane-Rathnayake R, Louthrenoo W, Chen YH, Cho J, Lateef A, Hamijoyo L, Luo SF, Wu YJ, Navarra SV, Zamora L, Li Z, Sockalingam S, Katsumata Y, Harigai M, Hao Y, Zhang Z, Basnayake BMDB, Chan M, Kikuchi J, Takeuchi T, Bae SC, Oon S, O'Neill S, Goldblatt F, Ng KPL, Law A, Tugnet N, Kumar S, Tee C, Tee M, Ohkubo N, Tanaka Y, Lau CS, Nikpour M, Hoi A, Morand EF; Asia Pacific Lupus Collaboration. Golder V, et al. J Rheumatol. 2024 May 1:jrheum.2023-0900. doi: 10.3899/jrheum.2023-0900. Online ahead of print. J Rheumatol. 2024. PMID: 38490668